Will Delivra Corp Short Squeeze Soon?

 Will Delivra Corp Short Squeeze Soon?

The stock of Delivra Corp (CVE:DVA) is a huge mover today! About 44,500 shares traded hands or 72.90% up from the average. Delivra Corp (CVE:DVA) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.
The move comes after 9 months negative chart setup for the $16.26M company. It was reported on Nov, 16 by Barchart.com. We have $0.46 PT which if reached, will make CVE:DVA worth $2.11 million less.

More notable recent Delivra Corp (CVE:DVA) news were published by: Marketwired.com which released: “Delivra Corp. Issues $2020900, 6% Unsecured Convertible Debentures” on September 15, 2016, also Marketwired.com with their article: “Delivra Corp. Announces Unsecured Convertible Debenture Financing” published on August 31, 2016, Marketwired.com published: “Delivra Announces Q2 2016 Financial Results” on August 29, 2016. More interesting news about Delivra Corp (CVE:DVA) were released by: Marketwired.com and their article: “Delivra Powers Diabetic Wound Healing” published on March 29, 2016 as well as Marketwired.com‘s news article titled: “Delivra Advances Revolutionary Treatment for Cardiovascular Disease” with publication date: November 03, 2016.

Delivra Corp., formerly Whiteknight Acquisitions III Inc., is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin. The company has a market cap of $16.26 million. The Firm makes and sells natural topical creams under its brand names, LivRelief, which is indicated for conditions, including joint and muscle pain, nerve pain, circulation and wound healing, and LivSport brand, which is indicated for sports performance. It currently has negative earnings. The Company’s business is divided into two areas of focus: Consumer Healthcare Over the Counter Retail products, and Technology Licensing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment